Security
TherapeuticsMD, Inc. Common Stock · TXMD
TXMDNASDAQCommon stockCurrentCIK 25743Updated Oct 6, 2026
Name history
AMHN, Inc. · through Sep 14, 2011CROFF ENTERPRISES INC · through Sep 4, 2009CROFF OIL CO · through Apr 1, 1997
TXMD price & chart
Loading TradingView…
NASDAQ:TXMD on TradingView ↗About the company
TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G/A - filed by Baselake Partners, LP regarding TherapeuticsMD, Inc.
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 38,671,000Source | — | 37,529,000Source | 38,504,000Source | 40,126,000Source | 37,581,000Source | 38,236,000Source | — | 37,656,000Source | 38,822,000Source | 43,309,000Source | 90,458,000Source |
| Property, Plant and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 78,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 3,914,000Source | — | 3,559,000Source | 4,043,000Source | 4,524,000Source | 3,667,000Source | 4,138,000Source | — | 3,761,000Source | 4,321,000Source | 6,098,000Source | 6,943,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | 5,745,000Source | — | — | 5,059,000Source | — | — |
| Assets, CurrentUSD | 14,503,000Source | — | 16,121,000Source | 13,461,000Source | 11,823,000Source | 15,263,000Source | 12,512,000Source | — | 14,445,000Source | 12,259,000Source | 11,796,000Source | 55,351,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,723,000Source | — | 3,538,000Source | 3,649,000Source | 3,683,000Source | 3,633,000Source | 3,771,000Source | — | 3,437,000Source | 3,638,000Source | 4,035,000Source | 6,034,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,515,000Source | — | 4,828,000Source | 5,732,000Source | 6,497,000Source | 5,062,000Source | 5,948,000Source | — | 5,293,000Source | 6,102,000Source | 6,873,000Source | 7,580,000Source |
| Other Assets, NoncurrentUSD | 470,000Source | — | 395,000Source | 428,000Source | 58,000Source | 419,000Source | 211,000Source | — | 444,000Source | 130,000Source | 58,000Source | 253,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 11,227,000Source | — | 10,397,000Source | 11,212,000Source | 12,456,000Source | 10,608,000Source | 11,496,000Source | — | 10,780,000Source | 11,452,000Source | 14,022,000Source | 55,315,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 11,000Source | — | 11,000Source | 11,000Source | 11,000Source | 11,000Source | 11,000Source | — | 11,000Source | 11,000Source | 11,000Source | 9,000Source |
| Additional Paid in CapitalUSD | — | — | — | — | 979,124,000Source | — | — | — | — | — | 978,917,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -951,772,000Source | — | -952,141,000Source | -951,924,000Source | -951,465,000Source | -952,296,000Source | -952,475,000Source | — | -952,391,000Source | -951,822,000Source | -949,641,000Source | -939,363,000Source |
| Stockholders' Equity Attributable to ParentUSD | 27,444,000Source | 27,094,000Source | 27,132,000Source | 27,292,000Source | 27,670,000Source | 26,973,000Source | 26,740,000Source | 28,664,000Source | 26,876,000Source | 27,370,000Source | 29,287,000Source | 35,143,000Source |
| Additional Paid in Capital, Common StockUSD | 979,205,000Source | — | 979,262,000Source | 979,205,000Source | — | 979,258,000Source | 979,204,000Source | — | 979,256,000Source | 979,181,000Source | — | 974,497,000Source |
| Liabilities and EquityUSD | 38,671,000Source | — | 37,529,000Source | 38,504,000Source | 40,126,000Source | 37,581,000Source | 38,236,000Source | — | 37,656,000Source | 38,822,000Source | 43,309,000Source | 90,458,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,945,000Source | — | 5,003,000Source | 4,662,000Source | 5,815,000Source | 4,911,000Source | 4,741,000Source | — | 4,785,000Source | 5,166,000Source | 6,854,000Source | 46,839,000Source |
| Operating Lease, Liability, CurrentUSD | 1,072,000Source | — | 1,039,000Source | 886,000Source | 1,589,000Source | 1,007,000Source | 1,011,000Source | — | 975,000Source | 1,633,000Source | 1,473,000Source | 1,390,000Source |
| Accounts Payable, CurrentUSD | 263,000Source | — | 460,000Source | 350,000Source | 143,000Source | 15,000Source | 176,000Source | — | 377,000Source | 258,000Source | 27,000Source | 2,162,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,411,000Source | — | 4,521,000Source | 5,718,000Source | — | 4,824,000Source | 5,960,000Source | — | 5,122,000Source | 5,542,000Source | 6,532,000Source | 7,369,000Source |
| Other Liabilities, NoncurrentUSD | 871,000Source | — | 873,000Source | 832,000Source | 637,000Source | 873,000Source | 795,000Source | — | 873,000Source | 744,000Source | 636,000Source | 1,107,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | —Source | —Source | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,000Source | 23,000Source | 75,000Source | 264,000Source | 1,271,000Source | 11,572,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -340,000Source | -82,000Source | 119,000Source | 231,000Source | -2,135,000Source | -1,211,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 7,115,000Source | 5,047,000Source | 9,189,000Source | 6,069,000Source | 8,419,000Source | 5,745,000Source | 7,483,000Source | 5,059,000Source | — | 64,907,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 13,545,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 33,000Source | — | 1,000Source | — | — | — | — | 1,300,000Source | 11,600,000Source |
| Amortization of Intangible AssetsUSD | — | — | 32,000Source | — | 13,000Source | — | — | 88,000Source | 176,000Source | — | 500,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | 100,000Source | 600,000Source |
| General and Administrative ExpenseUSD | — | — | 1,518,000Source | 1,585,000Source | 1,577,000Source | 1,551,000Source | 1,353,000Source | 1,491,000Source | 6,852,000Source | — | 8,903,000Source | 57,903,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | 50,000Source | -567,000Source | 164,000Source | 545,000Source | 103,000Source | -636,000Source | -653,000Source | -2,312,000Source | -7,699,000Source | 1,074,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 102,000Source | -42,000Source | -9,000Source | 6,000Source | -8,000Source | -17,000Source | 84,000Source | 131,000Source | -2,579,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | 110,923,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | -32,000Source | — | -31,000Source | -43,000Source | — |
| Investment Income, InterestUSD | — | — | — | — | 69,000Source | 29,000Source | 41,000Source | 29,000Source | 142,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 152,000Source | -609,000Source | 155,000Source | 551,000Source | 95,000Source | -653,000Source | -569,000Source | -2,181,000Source | -10,278,000Source | 111,997,000Source |
| Nonoperating Income (Expense)USD | — | — | 912,000Source | 567,000Source | 980,000Source | 1,240,000Source | 826,000Source | 613,000Source | 3,737,000Source | 2,417,000Source | 781,000Source | -117,000Source |
| Operating ExpensesUSD | — | — | 1,646,000Source | 1,681,000Source | 1,685,000Source | 1,647,000Source | 1,447,000Source | 1,674,000Source | 7,412,000Source | 6,521,000Source | 9,825,000Source | 67,375,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,400,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | -117,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 1,622,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 3,151,000Source | 2,454,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 784,000Source | 547,000Source | 869,000Source | 952,000Source | 724,000Source | 393,000Source | 3,022,000Source | 1,761,000Source | 300,000Source | 69,963,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | 1,761,000Source | 1,302,000Source | 69,963,000Source |
| Cost of RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 1,397,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | 1,551,000Source | — | 1,081,000Source | — | 4,744,000Source | — | — |
| Operating Income (Loss)USD | — | — | -862,000Source | -1,134,000Source | -816,000Source | -695,000Source | -723,000Source | -1,281,000Source | -4,390,000Source | -4,760,000Source | -8,523,000Source | 1,191,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | -117,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 50,000Source | -567,000Source | 164,000Source | 545,000Source | 103,000Source | -668,000Source | -653,000Source | -2,343,000Source | -7,742,000Source | 1,074,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | -32,000Source | — | -31,000Source | -43,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 152,000Source | -609,000Source | 155,000Source | 551,000Source | 95,000Source | -653,000Source | -569,000Source | -2,181,000Source | -10,278,000Source | 111,997,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.01Source | -0.05Source | 0.01Source | 0.05Source | 0.01Source | -0.06Source | -0.05Source | -0.19Source | -0.98Source | 12.41Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.01Source | -0.05Source | 0.01Source | 0.05Source | 0.01Source | -0.06Source | -0.05Source | -0.19Source | -0.98Source | 11.96Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 11,574,000Source | 11,532,000Source | 11,574,000Source | 11,574,000Source | 11,574Source | 11,552Source | 11,569,000Source | 11,532Source | 10,441,000Source | 9,028,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 11,574,000Source | 11,532,000Source | 11,643,000Source | 11,574,000Source | 11,640Source | 11,552Source | 11,569,000Source | 11,532Source | 10,441,000Source | 9,366,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 32,000Source | — | 13,000Source | — | — | 88,000Source | 176,000Source | — | 500,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 96,000Source | 96,000Source | 95,000Source | 96,000Source | 94,000Source | 95,000Source | 384,000Source | 509,000Source | 922,000Source | 1,193,000Source |
| General and Administrative ExpenseUSD | — | — | 1,518,000Source | 1,585,000Source | 1,577,000Source | 1,551,000Source | 1,353,000Source | 1,491,000Source | 6,852,000Source | — | 8,903,000Source | 57,903,000Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | 1,302,000Source | 68,566,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | 50,000Source | -567,000Source | 164,000Source | 545,000Source | 103,000Source | -636,000Source | -653,000Source | -2,312,000Source | -7,699,000Source | 1,074,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -653,000Source | — | — | 1,074,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | 0Source | -0.05Source | 0.01Source | 0.05Source | 0.01Source | -0.06Source | -0.06Source | -0.2Source | -0.74Source | 0.12Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | 0Source | -0.05Source | 0.01Source | 0.05Source | 0.01Source | -0.06Source | -0.06Source | -0.2Source | -0.74Source | 0.11Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 102,000Source | -42,000Source | -9,000Source | 6,000Source | -8,000Source | -17,000Source | 84,000Source | 131,000Source | -2,579,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | 110,923,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 300,000Source | 36,065,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | 8,000Source | 9,500Source | — | 13,545,000Source |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | 150,000Source | 144,900Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | 69,000Source | 29,000Source | 41,000Source | 29,000Source | 142,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 912,000Source | 567,000Source | 980,000Source | 1,240,000Source | 826,000Source | 613,000Source | 3,737,000Source | 2,417,000Source | 781,000Source | -117,000Source |
| Operating ExpensesUSD | — | — | 1,646,000Source | 1,681,000Source | 1,685,000Source | 1,647,000Source | 1,447,000Source | 1,674,000Source | 7,412,000Source | 6,521,000Source | 9,825,000Source | 67,375,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,400,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 784,000Source | 547,000Source | 869,000Source | 952,000Source | 724,000Source | 393,000Source | 3,022,000Source | 1,761,000Source | 300,000Source | 69,963,000Source |
| Total Revenue | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
Filing attachments
ea029897901ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ea029897901ex99-1.htm PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED AUGUST 11, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS." Exhibit 99.1 FOR IMMEDIATE RELEASE TherapeuticsMD Announces Second Quarter 2026 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE) - August 11, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the…
Read attachment ↗ea028977601ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 ea028977601ex99-1.htm PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MAY 12, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS." Exhibit 99.1 TherapeuticsMD Announces First Quarter 2026 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE) - May 12, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2…
Read attachment ↗ea028323901ex99-1.htm · 8-K · 2026-03-30
EX-99.1 2 ea028323901ex99-1.htm PRESS RELEASE Exhibit 99.1 TherapeuticsMD Announces Full Year 2025 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE) - March 30, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(…
Read attachment ↗ea026541601ex99-1_therape.htm · 8-K · 2025-11-13
EX-99.1 2 ea026541601ex99-1_therape.htm PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED NOVEMBER 12, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS." Exhibit 99.1 TherapeuticsMD Announces Third Quarter 2025 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE) - November 12, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months…
Read attachment ↗ea025234801ex99-1_therap.htm · 8-K · 2025-08-12
EX-99.1 2 ea025234801ex99-1_therap.htm PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED AUGUST 12, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS." Exhibit 99.1 TherapeuticsMD Announces Second Quarter 2025 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE) - August 12, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months en…
Read attachment ↗ea024198601ex99-1_therap.htm · 8-K · 2025-05-13
EX-99.1 2 ea024198601ex99-1_therap.htm PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MAY 13, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS" Exhibit 99.1 TherapeuticsMD Announces First Quarter 2025 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE) - May 13, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March…
Read attachment ↗